Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DIRECT-2: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in HR+, HER2- Breast Cancer

NCT05503108 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT05503108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05503108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DIRECT-2: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in HR+, HER2- Breast Cancer
Lead sponsor
Leiden University Medical Center
Phase
Phase 3
Overall status
Suspended
Start date
March 17, 2023
Completion date
January 1, 2024
Enrollment
10 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fasting mimicking diet, her2-negative breast cancer, hormone receptor-positive breast cancer, neoadjuvant chemotherapy, objective response rate, pathological complete response